Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Catalyst Crew Technologies Corp. entered into an asset purchase agreement with Kevin Rodan Levy, an individual seller and a related party to the company. The buyer will acquire all assets relating to an artificial intelligence-enabled healthcare analytics system (the AI Healthcare Platform) and a technology-enabled healthcare services coordination platform (the Healthcare Services Platform), including related intellectual property.
The agreement provides that the buyer will not assume liabilities of the seller or the assets except as expressly set forth in a written instrument at closing, while the seller retains responsibility for liabilities arising prior to closing, including taxes, contractual obligations, employment-related obligations, and regulatory liabilities. The purchase consideration includes the issuance of 12,000,000 restricted shares of Catalyst Crew Technologies to the seller.
Filed under
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026